These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24195097)

  • 1. Pyoderma gangrenosum and tumor necrosis factor α agents.
    Rallis E; Koumantaki-Mathioudaki E; Tsiatoura A; Stavropoulos P; Katsambas A
    Cutis; 2013 Oct; 92(4):E1-2. PubMed ID: 24195097
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
    Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
    Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
    Pastor N; Betlloch I; Pascual JC; Blanes M; Bañuls J; Silvestre JF
    Clin Exp Dermatol; 2006 Jan; 31(1):152-3. PubMed ID: 16309525
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
    Batres LA; Mamula P; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
    Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
    Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade.
    Ito T; Sato N; Yamazaki H; Koike T; Emura I; Saeki T
    Mod Rheumatol; 2013 Jan; 23(1):195-9. PubMed ID: 22526827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe recalcitrant pyoderma gangrenosum treated with infliximab.
    Kaur MR; Lewis HM
    Br J Dermatol; 2005 Sep; 153(3):689-91. PubMed ID: 16120178
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy of etanercept for treatment of PAPA syndrome.
    Tofteland ND; Shaver TS
    J Clin Rheumatol; 2010 Aug; 16(5):244-5. PubMed ID: 20661073
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.
    Ferkolj I; Hocevar A; Golouh R; Dolenc Voljc M
    Acta Dermatovenerol Alp Pannonica Adriat; 2006 Dec; 15(4):173-7. PubMed ID: 17982610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid improvement of pyoderma gangrenosum after treatment with infliximab.
    Chan JL; Graves MS; Cockerell CJ; Pandya AG
    J Drugs Dermatol; 2010 Jun; 9(6):702-4. PubMed ID: 20645536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
    Adişen E; Oztaş M; Gürer MA
    Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.